AtriCure to Participate at the Morgan Stanley 17th Annual Global Healthcare Conference
August 26 2019 - 7:00AM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a
leading innovator in surgical treatments for atrial fibrillation
(Afib) and left atrial appendage management, today announced that
the company will be participating in the upcoming Morgan Stanley
17th Annual Global Healthcare Conference in New York City.
AtriCure’s management is scheduled to present on Monday,
September 9, 2019, at 2:15 p.m. Eastern Time. Interested parties
may access a live audio webcast of the presentation by visiting the
“Investors” section of the company’s website at
https://ir.atricure.com.
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first and only
medical device to receive FDA approval for the treatment of
persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage
Exclusion System products are the most widely sold LAA management
devices worldwide. For more information, visit
AtriCure.com or follow us on Twitter
@AtriCure.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190826005077/en/
Andy Wade AtriCure, Inc. Senior Vice President and Chief
Financial Officer (513) 755-4564 awade@atricure.com
Lynn Pieper Lewis Gilmartin Group Investor Relations (415)
937-5402 lynn@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Apr 2024 to May 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From May 2023 to May 2024